🔬 Q-Line Biotech IPO Subscription Day 1 — 21 May 2026
The Q-Line Biotech IPO opened for subscription today on 21 May 2026 on NSE SME. This healthcare diagnostics company is raising ₹214 crore — one of the largest SME IPOs of 2026 — at ₹326–₹343 per share. Issue closes 25 May, allotment 26 May, listing 29 May 2026.
📊 Day 1 Subscription Status — Category Wise
• Overall Subscription: Day 1 data for Q-Line Biotech IPO subscription is building. Given GMP of ₹155, strong oversubscription expected by Day 3.
• Retail (RII) Category: Retail quota 35%. Bids being recorded. Apply early — this issue likely to see high retail rush on Day 3.
• NII / HNI Category: NII quota 15%. Strong HNI interest expected given GMP of ₹155 (+45.19%).
• QIB Category: QIB quota 50%. With ₹214 Cr issue size, institutional Day 3 bids will be critical. Track live on IPOView.
• IPOView Assessment: Star IPO of the week. GMP ₹155 is the highest among all current open IPOs. Pre-IPO placement at ₹343 shows institutional confidence. High-conviction investors should apply early.
📈 Q-Line Biotech IPO GMP Today — 21 May 2026
The Q-Line Biotech IPO GMP today is ₹155 (+45.19%), indicating expected listing price of ~₹498. This is the strongest GMP among all open IPOs. Track live on IPOView GMP Tracker.
📋 IPO Key Details
• Exchange: NSE SME | Price Band: ₹326–₹343 | Issue Size: ₹214 Cr (Fresh Issue)
• Lot Size: 400 shares | Min. Investment: ₹2,74,400 (2 lots = 800 shares)
• Open: 21 May | Close: 25 May | Allotment: 26 May | Listing: 29 May 2026
• Registrar: Purva Sharegistry | Lead Managers: HEM Securities + Share India Capital
🏭 About Q-Line Biotech Ltd
Q-Line Biotech, incorporated 2010, Delhi. Develops, manufactures, and markets IVD kits, diagnostic reagents, pathology products, and medical diagnostic equipment. Serves 150+ national and international clients. 362 permanent + 223 contract employees. Revenue FY25: ₹322.58 Cr (vs ₹206.45 Cr FY24).
Disclaimer: Not investment advice. Read RHP carefully. GMP is unofficial and unregulated.